Annika Ericsson

Annika Ericsson is a seasoned professional in the field of scientific research and development, currently serving as the Chief Scientific Officer at CombiGene since December 2018, where Annika has also held roles as Director of Preclinical Development, Preclinical Project Manager, and Senior Project Manager. Prior to their tenure at CombiGene, Annika Ericsson worked as a Senior Scientist in Preclinical at Chiesi Group from June 2018 to December 2018 and spent over a decade at Zymenex A/S as a Senior Scientist from September 2005 to May 2018. Annika Ericsson's early career included a Postdoctoral Fellowship at Mount Sinai School of Medicine, focusing on a mouse model for congenital erythropoietic porphyria and gene therapy, following a PhD at Karolinska Institutet, where research concentrated on innovative treatments for acute intermittent porphyria. Educationally, Annika Ericsson holds a Master of Science in Biology from Linköping University, obtained between 1995 and 1999.